Filing Flows › Comparisons › EVMN vs ZOMDF
Evommune vs Zomedica: EVMN and ZOMDF compared
Evommune is the larger company: $10.0M of revenue in its latest quarter (Q3 2025) against $9.9M for Zomedica (Q3 2026). Zomedica is more profitable, with an operating margin of -34.6% against -133.3%.
Where the money goes: EVMN and ZOMDF
Evommune (EVMN) · Q3 2025
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
Zomedica (ZOMDF) · Q3 2026
Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%, net loss $3.2M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Evommune (EVMN) | Zomedica (ZOMDF) | |
|---|---|---|
| Latest quarter | Q3 2025 | Q3 2026 |
| Revenue | $10.0M | $9.9M |
| Revenue growth, Y/Y | — | +22% |
| Operating margin | -133.3% | -34.6% |
| Net earnings | −$12.5M | −$3.2M |
| Net margin | -124.8% | -32.0% |
| Operating cash flow | −$9.6M | −$2.8M |
Where the revenue comes from
Zomedica
- Consumables: $6.8M (69%)
- Capital: $2.0M (20%)
- Engineering: $981K (10%)
- Other: $116K (1%)
Questions
Which is bigger, Evommune or Zomedica?
Evommune is the larger company: $10.0M of revenue in its latest quarter (Q3 2025) against $9.9M for Zomedica (Q3 2026).
Is Evommune or Zomedica growing faster?
Zomedica is more profitable, with an operating margin of -34.6% against -133.3%.
More: Evommune earnings · how Evommune makes money · Zomedica earnings · how Zomedica makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Dec 11, 2025; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.